USE OF BUPROPION IN PATIENTS WHO EXHIBIT ORTHOSTATIC HYPOTENSION ON TRICYCLIC ANTI-DEPRESSANTS
- 1 January 1983
- journal article
- research article
- Vol. 44 (5) , 170-173
Abstract
Patients who developed clinically significant and documented orthostatic hypotension during treatment with tricyclic antidepressants were withdrawn from the tricyclic for at least 5 days. During a baseline period of 3-7 days a placebo identical to bupropion was then administered. A baseline ECG, psychiatric scale ratings, vital signs, clinical laboratory and physical exam were performed on those patients on placebo who were free of orthostatic hypotension for 3 consecutive days. Patients were then transferred to an ascending dosage regimen of bupropion. Only patients who were treated with bupropion for at least 7 days and who received a daily dose of at least 450 mg were considered to have completed the study. The results in 12 inpatients in 2 centers showed that bupropion produced no clinically significant alterations in pulse rate, systolic blood pressure or orthostasis as compared to placebo in patients who had clinically significant orthostatic hypotension caused by tricyclic treatment.This publication has 5 references indexed in Scilit:
- THE CARDIOVASCULAR PROFILE OF BUPROPION1983
- REVIEW OF PLACEBO-CONTROLLED TRIALS WITH BUPROPION1983
- A DOUBLE-BLIND COMPARISON OF BUPROPION AND AMITRIPTYLINE IN DEPRESSED INPATIENTS1983
- CLINICAL CHARACTERISTICS OF IMIPRAMINE-INDUCED ORTHOSTATIC HYPOTENSIONThe Lancet, 1979
- The hypotensive effect of imipramine hydrochloride in patients with cardiovascular diseaseClinical Pharmacology & Therapeutics, 1961